Mylan Inc.'s MYL -0.04% second-quarter earnings surged 70% as the generic-drug maker's sales got a boost from a weaker dollar and its posted litigation-related and other charges. Adjusted profit and revenue beat analysts' expectations. For the year, the company tightened its per-share earnings forecast to $1.95 to $2.05 from its prior projection of $1.90 to $2.10, and affirmed its revenue view. Mylan--the world's third-largest generic-drug maker by sales, after Novartis AG's (NVS, NOVN.VX) generic arm Sandoz and Teva Pharmaceuticals Industries Ltd. (TEVA, TEVA.TV) -- has continued to report stronger revenue in recent quarters, though litigation and acquisition-related expenses have weighed on the bottom line. Mylan reported a profit of $146.4 million, or 33 cents a share, up from $86.2 million, or 16 cents a share, a year earlier. Excluding litigation impacts and other items, earnings were up at 52 cents from 37 cents. Revenue increased 15% to $1.57 billion, with currency fluctuations adding about 5 percentage points to the growth. Analysts polled by Thomson Reuters most recently forecast earnings of 45 cents on revenue of $1.49 billion. Gross margin climbed to 45.5% from 39.6%. Generic sales, which represent the vast majority of the companies revenue, were up 16% amid 27% growth in North America and 17% growth in the Asia Pacific region. Shares closed Tuesday at $23.55 and were inactive premarket. The stock is up 30% in the past year.

Source